Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 9
2003 3
2004 5
2005 7
2006 10
2007 10
2008 8
2009 5
2010 7
2011 13
2012 8
2013 3
2014 1
2015 10
2016 8
2017 25
2018 30
2019 26
2020 28
2021 31
2022 25
2023 27
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

286 results

Results by year

Filters applied: . Clear all
Page 1
Global spread of Carbapenemase-producing Enterobacteriaceae.
Nordmann P, Naas T, Poirel L. Nordmann P, et al. Among authors: naas t. Emerg Infect Dis. 2011 Oct;17(10):1791-8. doi: 10.3201/eid1710.110655. Emerg Infect Dis. 2011. PMID: 22000347 Free PMC article. Review.
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M, Echols R, Matsunaga Y, Ariyasu M, Doi Y, Ferrer R, Lodise TP, Naas T, Niki Y, Paterson DL, Portsmouth S, Torre-Cisneros J, Toyoizumi K, Wunderink RG, Nagata TD. Bassetti M, et al. Among authors: naas t. Lancet Infect Dis. 2021 Feb;21(2):226-240. doi: 10.1016/S1473-3099(20)30796-9. Epub 2020 Oct 12. Lancet Infect Dis. 2021. PMID: 33058795 Clinical Trial.
β-Lactamase Genes without Limits.
Naas T, Dabos L, Bonnin RA. Naas T, et al. Microorganisms. 2023 May 4;11(5):1200. doi: 10.3390/microorganisms11051200. Microorganisms. 2023. PMID: 37317173 Free PMC article.
Antimicrobial Peptides: A Potent Alternative to Antibiotics.
Rima M, Rima M, Fajloun Z, Sabatier JM, Bechinger B, Naas T. Rima M, et al. Among authors: naas t. Antibiotics (Basel). 2021 Sep 10;10(9):1095. doi: 10.3390/antibiotics10091095. Antibiotics (Basel). 2021. PMID: 34572678 Free PMC article. Review.
Clinical bacteriology in low-resource settings: today's solutions.
Ombelet S, Ronat JB, Walsh T, Yansouni CP, Cox J, Vlieghe E, Martiny D, Semret M, Vandenberg O, Jacobs J; Bacteriology in Low Resource Settings working group. Ombelet S, et al. Lancet Infect Dis. 2018 Aug;18(8):e248-e258. doi: 10.1016/S1473-3099(18)30093-8. Epub 2018 Mar 5. Lancet Infect Dis. 2018. PMID: 29519767 Review.
Pseudomonasaeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID/ISARPAE Group.
Oliver A, Rojo-Molinero E, Arca-Suarez J, Beşli Y, Bogaerts P, Cantón R, Cimen C, Croughs PD, Denis O, Giske CG, Graells T, Daniel Huang TD, Iorga BI, Karatuna O, Kocsis B, Kronenberg A, López-Causapé C, Malhotra-Kumar S, Martínez LM, Mazzariol A, Meyer S, Naas T, Notermans DW, Oteo-Iglesias J, Pedersen T, Pirš M, Poeta P, Poirel L, Pournaras S, Sundsfjord A, Szabó D, Tambić-Andrašević A, Vatcheva-Dobrevska R, Vitkauskienė A, Jeannot K; ESGARS-ISARPAE members. Oliver A, et al. Among authors: naas t. Clin Microbiol Infect. 2024 Apr;30(4):469-480. doi: 10.1016/j.cmi.2023.12.026. Epub 2023 Dec 30. Clin Microbiol Infect. 2024. PMID: 38160753 Free article.
Activity of mecillinam against carbapenem-resistant Enterobacterales.
Emeraud C, Godmer A, Girlich D, Vanparis O, Mahamdi F, Creton E, Jousset AB, Naas T, Bonnin RA, Dortet L. Emeraud C, et al. Among authors: naas t. J Antimicrob Chemother. 2022 Sep 30;77(10):2835-2839. doi: 10.1093/jac/dkac226. J Antimicrob Chemother. 2022. PMID: 35815675 Free PMC article.
286 results